Senate Holds Hearing on 340B Drug Pricing Program
Conclusion
Given the widespread support for the 340B program, it is likely that it is here to stay. What remains to be seen, however, is whether Congress will work to reign in the out-of-control side of it and modify it back on a sustainable path like was initially intended.
Related StoriesHouse of Representatives Holds Two-Day Hearing on OpioidsHigher Outpatient Drug Spending At 340B Hospitals, According to New AnalysisHouse Subcommittee on Health Holds Hearing on MACRA
Source: Policy and Medicine - Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
More News: American Health | Education | Grants | Health Management | Pensions | Politics | Primary Care | Uninsured | Universities & Medical Training | USA Health